<DOC>
	<DOCNO>NCT00148356</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy ZoMaxx drug-eluting stent patient blockage native coronary artery . The study design demonstrate non-inferiority TAXUS Express2 Paclitaxel-Eluting Stent proven superior bare metal stent recognize standard care .</brief_summary>
	<brief_title>Safety Efficacy ZoMaxx™ Drug-Eluting Stent System Coronary Arteries</brief_title>
	<detailed_description>Heart disease lead cause death Europe whole , mortality rate cardiovascular disease decrease western European country , due expand use prevention strategy well treatment , coronary heart disease mortality middle age group increase rapidly country Eastern Europe . The number procedure perform treat cardiovascular disease Europe constantly increase , although different type procedure exhibit different trend . Percutaneous coronary intervention ( PCI ) procedure , example , total 430,000 European Union ( 15 country ) 520,000 Europe whole ( 33 country ) 2000 , report Euro Heart Survey , growth continue rate 20 % per year . Despite effectiveness intracoronary stent maintain large luminal diameter compare angioplasty alone , 15 - 35 % in-stent restenosis occur within 6 9 month stent placement . While stent reduce restenosis block vascular recoil remodeling , mechanical intervention alone incapable treat biological problem neointimal hyperplasia . Various approach use treat in-stent restenosis , include balloon angioplasty , repeat stenting , rotational directional atherectomy , laser local use radiation time stenting ( brachytherapy ) . However , technique add complexity interventional procedure document success prevent restenosis . Drug-eluting stent ( DES ) use antiproliferative agent deliver via polymer base stent platform show significant success reduction restenosis de novo lesion traditional bare metal stent randomize clinical trial . Local delivery pharmacological agent allow control delivery high drug concentration target tissue maximize systemic drug effect . The ZoMaxx I Trial study ZoMaxx Drug Eluting Coronary Stent System ( ZoMaxx DES ) evaluate potential benefit local application zotarolimus drug combination phosphorylcholine ( PC ) -coated tri-metal stent . ZoMaxx™ Drug-Eluting Stent System Investigational device . Limited Federal ( U.S. ) law investigational use .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria include follow : Subject ≥ 18 year old . Female childbearing potential must negative pregnancy test within 7 day prior enrollment utilize reliable birth control nine ( 9 ) month enrollment . Subject eligible percutaneous coronary intervention ( PCI ) single lesion require treatment . Subject acceptable candidate CABG . Subject clinical evidence ischemic heart disease positive functional study . Subject document stable angina pectoris Exclusion Criteria include follow : Evidence acute myocardial infarction ( AMI ) CKMB &gt; 2x upper limit normal within 72 hour intend treatment ( refer WHO definition ) . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix® ) ticlopidine ( Ticlid® ) , heparin , stainless steel , tantalum , contrast agent ( adequately premedicated ) , paclitaxel , drug similar ABT578 ( i.e . tacrolimus , sirolimus , everolimus ) . A platelet count &lt; 100 x 109/L &gt; 700 x 109/L ( &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 ) ; WBC &lt; 3,000 cells/mm3 ; hemoglobin &lt; 10.0 g/dl . Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150 µmol/L ) . Subject previous plan brachytherapy target vessel . Target vessel evidence thrombus excessively tortuous ( &gt; 60 degree bend ) make unsuitable proper stent delivery deployment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
</DOC>